|
1
|
Liu Y, Yao Q and Zhang F: Diagnosis,
prognosis and treatment of primary central nervous system lymphoma
in the elderly population (Review). Int J Oncol. 58:371–387. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shao L, Xu C, Wu H, Jamal M, Pan S, Li S,
Chen F, Yu D, Liu K and Wei Y: Recent progress on primary central
nervous system lymphoma-From bench to bedside. Front Oncol.
11:6898432021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferreri AJM, Calimeri T, Cwynarski K,
Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L,
Ponzoni M and Batchelor TT: Primary central nervous system
lymphoma. Nat Rev Dis Primers. 9:292023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
D'Angelo CR: Diagnostic, pathologic, and
therapeutic considerations for primary CNS lymphoma. JCO Oncol
Pract. 20:195–202. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Green K, Munakomi S and Hogg JP: Central
nervous system lymphoma. StatPearls [Internet] Treasure Island
(FL): StatPearls Publishing; 2024
|
|
6
|
Schaff LR and Grommes C: Primary central
nervous system lymphoma. Blood. 140:971–979. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Koning ME, Hof JJ, Jansen C, Doorduijn
JK, Bromberg JEC and van der Meulen M: Primary central nervous
system lymphoma. J Neurol. 271:2906–2913. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lebrun L, Allard-Demoustiez S and Salmon
I: Pathology and new insights in central nervous system lymphomas.
Curr Opin Oncol. 35:347–356. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jin Q, Jiang H, Han Y, Zhang L, Li C,
Zhang Y, Chai Y, Zeng P, Yue L and Wu C: Tumor microenvironment in
primary central nervous system lymphoma (PCNSL). Cancer Biol Ther.
25:24251312024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bödör C, Alpár D, Marosvári D, Galik B,
Rajnai H, Bátai B, Nagy Á, Kajtár B, Burján A, Deák B, et al:
Molecular subtypes and genomic profile of primary central nervous
system lymphoma. J Neuropathol Exp Neurol. 79:176–183. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hans CP: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Joshi A, Deshpande S and Bayaskar M:
Primary CNS lymphoma in immunocompetent patients: Appearances on
conventional and advanced imaging with review of literature. J
Radiol Case Rep. 16:1–17. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Radotra BD, Parkhi M, Chatterjee D, Yadav
BS, Ballari NR, Prakash G and Gupta SK: Clinicopathological
features of primary central nervous system diffuse large B cell
lymphoma: Experience from a tertiary center in North India. Surg
Neurol Int. 11:4242020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ribas GA, de Mori LH, Freddi TAL, Oliveira
LDS, de Souza SR and Corrêa DG: Primary central nervous system
lymphoma: Imaging features and differential diagnosis. Neuroradiol
J. 37:705–722. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Wang Y and Liu Y, Liu Z, Cui Q, Ji
N, Sun S, Wang B, Wang Y, Sun X and Liu Y: Immunohistochemical
profile and prognostic significance in primary central nervous
system lymphoma: Analysis of 89 cases. Oncol Lett. 14:5505–5512.
2017.PubMed/NCBI
|
|
16
|
Puligundla CK, Bala S, Karnam AK, Gundeti
S, Paul TR, Uppin MS and Maddali LS: Clinicopathological features
and outcomes in primary central nervous system lymphoma: A 10-year
experience. Indian J Med Paediatric Oncol. 38:478–482. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Du KX, Shen HR, Pan BH, Luthuli S, Wang L,
Liang JH, Li Y, Yin H, Li JY, Wu JZ and Xu W: Prognostic value of
POD18 combined with improved IELSG in primary central nervous
system lymphoma. Clin Transl Oncol. 26:720–731. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yokogami K, Azuma M, Takeshima H and Hirai
T: Lymphomas of the central nervous system. Adv Exp Med Biol.
1405:527–543. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Provenzale JM, Mukundan S and Dewhirst M:
The role of blood-brain barrier permeability in brain tumor imaging
and therapeutics. AJR Am J Roentgenol. 185:763–767. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
White NS, McDonald CR, Farid N, Kuperman
JM, Kesari S and Dale AM: Improved conspicuity and delineation of
high-grade primary and metastatic brain tumors using ‘restriction
spectrum imaging’: Quantitative comparison with high B-value DWI
and ADC. AJNR Am J Neuroradiol. 34:958–964. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahn SJ, Shin HJ, Chang JH and Lee SK:
Differentiation between primary cerebral lymphoma and glioblastoma
using the apparent diffusion coefficient: Comparison of three
different ROI methods. PLoS One. 9:e1129482014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Xia J, Zhou YC, Xia LM, Zhu WZ,
Zou ML, Feng DY and Wang CY: Correlation between magnetic resonance
diffusion-weighted imaging and cell density in astrocytoma.
Zhonghua Zhong Liu Za Zhi. 27:309–311. 2005.(In Chinese).
PubMed/NCBI
|
|
23
|
Guo AC, Cummings TJ, Dash RC and
Provenzale JM: Lymphomas and high-grade astrocytomas: Comparison of
water diffusibility and histologic characteristics. Radiology.
224:177–183. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schob S, Meyer J, Gawlitza M,
Frydrychowicz C, Müller W, Preuss M, Bure L, Quäschling U, Hoffmann
KT and Surov A: Diffusion-weighted MRI reflects proliferative
activity in primary CNS lymphoma. PLoS One. 11:e01613862016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Surov A, Meyer HJ and Wienke A:
Correlation between apparent diffusion coefficient (ADC) and
cellularity is different in several tumors: A meta-analysis.
Oncotarget. 8:59492–59499. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morales-Martinez A, Nichelli L,
Hernandez-Verdin I, Houillier C, Alentorn A and Hoang-Xuan K:
Prognostic factors in primary central nervous system lymphoma. Curr
Opin Oncol. 34:676–684. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Momota H, Narita Y, Maeshima AM, Miyakita
Y, Shinomiya A, Maruyama T, Muragaki Y and Shibui S: Prognostic
value of immunohistochemical profile and response to high-dose
methotrexate therapy in primary CNS lymphoma. J Neurooncol.
98:341–348. 2010. View Article : Google Scholar : PubMed/NCBI
|
